Parkinson’s Disease: Nutritional Considerations

1. Anderson C, Checkoway H, Franklin GM, Beresford S, Smith–Weller T, Swanson PD. Dietary factors in Parkinson’s disease: the role of food groups and specific foods. Movement Disorder. 1999;14:21–27.

2. Logroscino G, Marder K, Cote L, Tang M–X, Shea S, Mayeux R. Dietary lipids and antioxidants in Parkinson’s disease: a population–based, case–control study. Ann Neurol.1996;39:89–94.

3. Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL. Adult nutrient intake as a risk factor for Parkinson's disease. Int J Epidemiol. 1999;28:1102–1109.

4. Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Diet and Parkinson’s disease: a potential role of dairy products in men. Ann Neurol. 2002;52:793–801.

5. Ascherio A, Weisskopf MG, O'Reilly EJ, et al.  Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol. 2004;160:977–984.

6. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease.
Neurology. 2003;60:790–795.

7. Tan EK, Tan C, Fook–Chong SM, et al. Dose–dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci. 2003;216:163–167.

8. Barichella M, Marczewska A, De Notaris R, et al. Special low–protein foods ameliorate postprandial off in patients with advanced Parkinson's disease. Mov Disord. 2006 Jun 13; DOI 10.1002/mds.21003.   

9. Pincus JH, Barry K. Protein redistribution diet restores motor function in patients with dopa–resistant "off" periods. Neurology. 1988;38:481–483.

10. Mena I, Cotzias GC. Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med. 1975;292:181–184.

11. Gillespie NG, Mena L, Cotzias GC, Bell MA. Diets affecting treatment of parkinsonism with levodopa. J Am Diet Assoc. 1973;62:525–528.

12. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.
Neurology. 2001;56:S1–S88.

13. Berry EM, Growdon JH, Wurtman JJ, Caballero B, Wurtman RJ. A balanced carbohydrate: protein diet in the management of Parkinson's disease. Neurology. 1991;41:1295–1297.

14. Di Stefano A, Sozio P, Cocco A, et al. L–dopa– and dopamine–(R)–alpha–lipoic acid conjugates as multifunctional codrugs with antioxidant properties. J Med Chem. 2006;49:1486–1493.

15. Verhoef P, de Groot LC. Dietary determinants of plasma homocysteine concentrations. Semin Vasc Med. 2005;5:110–123.

16. Lamberti P, Zoccolello S, Armanese E, et al. Hyperhomocysteinemia in L–dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol. 2005;12:365–368.

17. Kempster PA, Wahlqvist ML. Dietary factors in the management of Parkinson's disease. Nutr Rev. 1994;52(2 pt 1):51–58.

18. Katzenschlager R, Evans A, Manson A. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry.2004;75:1672–1677.  

19. Sucherowsky O, Gronseth G, Perlmutter J, et al. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence–based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:976–982.

20. Camarota SA, McArdle N. Where immigrants live: an examination of state residency of the foreign born by country of origin in 1990 and 2000. [Center for Immigration Studies Web site]. September, 2003. Available at: http://www.cis.org/articles/2003/back1203.html#table1. Accessed July 1, 2006.

21. Hald A, Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol. 2005;193:279–290.

22. Liu J, Ames BN. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr Neurosci. 2005;8:67–89.

23. Buhmann C, Arlt S, Kontush A, et al. Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication. Neurobiol Dis. 2004;15:160–170.

24. Pham DQ, Plakogiannis R. Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: part 2. Ann Pharmacother 2005;39:2065–2072.